The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Open accessAbstract
The interest on targeting adenosine A(2A) receptors in the realm of psychiatric diseases first arose based on their tight physical and functional interaction with dopamine D(2) receptors. However, the role of central A(2A) receptors is now viewed as much broader than just controlling D(2) receptor function. Thus, there is currently a major interest in the ability of A(2A) receptors to control synaptic plasticity at glutamatergic synapses. This is due to a combined ability of A(2A) receptors to facilitate the release of glutamate and the activation of NMDA receptors. Therefore, A(2A) receptors are now conceived as a normalizing device promoting adequate adaptive responses in neuronal circuits, a role similar to that fulfilled, in essence, by dopamine. This makes A(2A) receptors particularly attractive targets to manage psychiatric disorders since adenosine may act as go-between glutamate and dopamine, two of the key players in mood processing. Furthermore, A(2A) receptors also control glia function and brain metabolic adaptation, two other emerging mechanisms to understand abnormal processing of mood, and A(2A) receptors are important players in controlling the demise of neurodegeneration, considered an amplificatory loop in psychiatric disorders. Current data only provide an indirect confirmation of this putative role of A(2A) receptors, based on the effects of caffeine (an antagonist of both A(1) and A(2A) receptors) in psychiatric disorders. However, the introduction of A(2A) receptors antagonists in clinics as anti-parkinsonian agents is hoped to bolster our knowledge on the role of A(2A) receptors in mood disorders in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 3×
“nontoxic) doses are the A1 and A2A adenosine receptors, where caffeine acts as a competitive antagonist [99,100].”
BackgroundMolecular genetics of attention-deficit/hyperactivity disorder
Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., Holmgren, M. A., & Sklar, P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.024 · Cited by 2,357
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“Concerning the NMDA hypofunction model of schizophrenia [221], adenosine A1 and A2A receptor agonists have been shown to prevent behavioural and EEG effects of NMDA antagonists [222,223].”
BackgroundNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Nomenclature and classification of purinoceptors.
Fredholm, B. B., Abbracchio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P., & Williams, M. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06782-1 · Cited by 1,585
Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
New insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221
The Psychobiology of Depression and Resilience to Stress: Implications for Prevention and Treatment
Southwick, S. M., Vythilingam, M., & Charney, D. S. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143948 · Cited by 1,160
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 1×
“The recent finding of increased basal D2 receptors occupancy by dopamine in schizophrenic patients [214,215] is compatible with a decreased adenosinergic tone, which via A2A-D2 receptor interaction would increase the affinity of D2 receptors for dopamine [27,213].”
BackgroundInteraction between BDNF and Serotonin: Role in Mood Disorders
Martinowich, K., & Lu, B. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301571 · Cited by 793 · cited 1×
“Thus, there is a continuous build-up and strengthening of the ‘neurotrophin hypothesis of depression’ (reviewed in [177,178]) and evidence is accumulating to suggest that A2A receptors are tight controllers of the actions of BDNF, either through transactivation in an acute manner [179–181] or normalization of its sign…”
BackgroundEffects of caffeine on human behavior
Smith, A. (2002) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(02)00096-0 · Cited by 741
Swanson, J. M., Kinsbourne, M., Nigg, J., Lanphear, B., Stefanatos, G. A., Volkow, N., Taylor, E., Casey, B. J., Castellanos, F. X., & Wadhwa, P. D. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9019-9 · Cited by 580 · cited 1×
“The search for the most probable genetic traits associated with ADHD has mainly targeted genes involved with catecholaminergic transmission, with a special focus on dopamine [249].”
BackgroundStevens (2002) · doi:10.1016/s0896-6273(02)01067-x · Cited by 543
Brookes, K., Xu, X., Chen, W., Zhou, K., Neale, B., Lowe, N., Aneey, R., Franke, B., Gill, M., Ebstein, R., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001869 · Cited by 533 · cited 1×
“[253,254].”
Chudasama, Y., & Robbins, T. W. (2006) · Biological Psychology · doi:10.1016/j.biopsycho.2006.01.005 · Cited by 484
Stimulants: Therapeutic Actions in ADHD
Arnsten, A. F. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301164 · Cited by 473 · cited 19×
“Thus, the heritability of ADHD has been estimated to be between 0.5 and 0.9, which makes it the most heritable mental disorder among children.”
BackgroundInfluentialAn Update on the Mechanisms of the Psychostimulant Effects of Caffeine
Ferré, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05196.x · Cited by 440 · cited 2×
“Regarding the dopaminergic involvement in schizophrenia, it is noteworthy that activation of adenosine A2A receptors reduces the affinity of dopaminergic D2 receptors for dopamine, being the probable mechanism underlying the antipsychotic-like profile of adenosine agonists [213], the hyperdopaminergic effect of caffei…”
BackgroundSelf-citationMolecular Genetics of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Mick, E. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.004 · Cited by 411 · cited 20×
“Thus, the heritability of ADHD has been estimated to be between 0.5 and 0.9, which makes it the most heritable mental disorder among children.”
BackgroundInfluentialThe functional neuroanatomy of mood disorders
Soares, J. C., & Mann, J. J. (1997) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00016-2 · Cited by 379 · cited 1×
“Taking as examples the case of depressive disorders (the plural reflecting the idea that they are multiple defined clinical entities), the brain areas affected are rather broad and too many biochemical and/or neurochemical (or morphological) traits have been reported to allow any of them to be considered pathognomonic…”
BackgroundRebola, N., Lujan, R., Cunha, R. A., & Mulle, C. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.023 · Cited by 376 · cited 12×
“These A2A receptors control both the release of glutamate [35,42,43] as well as NMDA receptors [44].”
BackgroundInfluentialSelf-citationHaskell, C. F., Kennedy, D. O., Wesnes, K. A., & Scholey, A. B. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2104-3 · Cited by 356
Inflammation, Depression and Dementia: Are they Connected?
Leonard, B. E. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9385-y · Cited by 342 · cited 1×
“Accordingly, there is no clear definition of particular brain circuits affected in these conditions, nor there is any agreement on whether these conditions are due to metabolic [8– 10] or neuroinflammatory deregulations [11,12].”
BackgroundAssociation between A2a receptor gene polymorphisms and caffeine-induced anxiety
Alsene, K., Deckert, J., Sand, P., & de Wit, H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300232 · Cited by 334
What's wrong with my mouse model?
Kalueff, A. V., Wheaton, M., & Murphy, D. L. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.01.023 · Cited by 285 · cited 1×
“In fact, there is currently no single animal model that satisfactory mimics the most common behavioural changes found in psychiatric disorders [15–17].”
BackgroundRétey, J. V., Adam, M., Khatami, R., Luhmann, U. F. O., Jung, H. H., Berger, W., & Landolt, H.-P. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100102 · Cited by 278 · cited 1×
“Finally, another polymorphism of the A2A receptor gene (1083TT genotype) is inversely correlated with caffeine consumption [139] and is related with the inter-individual sensitivity to caffeine [140].”
BackgroundShould Depressive Syndromes Be Reclassified as “Metabolic Syndrome Type II”?
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., Woldeyohannes, H. O., Law, C. W. Y., Miranda, A., Fulgosi, D., & Kennedy, S. H. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701653377 · Cited by 277
Caffeine Reduces Low-Frequency Delta Activity in the Human Sleep EEG
Landolt, H. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00079-f · Cited by 198 · cited 1×
“Furthermore, there are co-morbidity relations, namely with insomnia (particularly with delta activity, see [198]), which is mimicked by caffeine consumption [199] and prevented by activation of adenosine receptors [117], and after seizures [200], which is also mimicked by xanthenes and prevented by adenosine A1 recept…”
BackgroundDunn, R. T., Kimbrell, T. A., Ketter, T. A., Frye, M. A., Willis, M. W., Luckenbaugh, D. A., & Post, R. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01244-6 · Cited by 184
Effects of the acute administration of caffeine in patients with schizophrenia
Lucas, P. B., Pickar, D., Kelsoe, J., Rapaport, M., Pato, C., & Hommer, D. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90429-6 · Cited by 125
Insulin signaling effects on memory and mood
Reagan, L. P. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.10.012 · Cited by 118 · cited 1×
“Accordingly, there is no clear definition of particular brain circuits affected in these conditions, nor there is any agreement on whether these conditions are due to metabolic [8– 10] or neuroinflammatory deregulations [11,12].”
BackgroundStructural plasticity and tianeptine: cellular and molecular targets
McEwen, B. S., Magarinos, A. M., & Reagan, L. P. (2002) · European Psychiatry · doi:10.1016/s0924-9338(02)00650-8 · Cited by 108
Cunha, G. M. A., Canas, P. M., Oliveira, C. R., & Cunha, R. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.024 · Cited by 108 · cited 2×
“In agreement with this role of synaptic A2A receptors in the control of brain tissue damage is the observation that A2A receptor antagonists prevented restraint stress-induced synaptic damage in the CA3 area of the rat hippocampus without any apparent involvement of changes in inflammatory-related cells [86].”
BackgroundResultSelf-citationKENDLER, K. S., MYERS, J., & O. GARDNER, C. (2006) · Psychological Medicine · doi:10.1017/s0033291706008622 · Cited by 96 · cited 2×
“Likewise, an analysis of life-long caffeine consumption in twin pairs failed to note any evident relation between caffeine intake and the risk for common psychiatric disorders [142].”
BackgroundThe effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers
Green, P. J., & Suls, J. (1996) · Journal of Behavioral Medicine · doi:10.1007/bf01857602 · Cited by 84 · cited 1×
“In fact, whereas higher doses of caffeine tend to increase [103,123–127] and lower doses of caffeine tend to reduce anxiety levels in Humans [128,129], it is currently difficult to ascribe these opposite effects to the a putative differential manipulation of A1 and A2A receptors.”
BackgroundAlcohol & Drug Abuse: Caffeine and Schizophrenia
Hughes, J. R., McHugh, P., & Holtzman, S. (1998) · Psychiatric Services · doi:10.1176/ps.49.11.1415 · Cited by 65
Attention Deficit Hyperactivity Disorder and Substance Use Disorders
Wilens, T. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.12.2059 · Cited by 16
Cited by
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Self-citationAdenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
Self-citationPurinergic signalling: From normal behaviour to pathological brain function
Burnstock, G., Krügel, U., Abbracchio, M. P., & Illes, P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.006 · Cited by 397
ATP as a multi-target danger signal in the brain
Rodrigues, R. J., Tomé, A. R., & Cunha, R. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00148 · Cited by 259
Self-citationRogers, P. J., Hohoff, C., Heatherley, S. V., Mullings, E. L., Maxfield, P. J., Evershed, R. P., Deckert, J., & Nutt, D. J. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.71 · Cited by 212
Metadata
- Authors
- Cunha, R., Ferre, S., Vaugeois, J.-M., & Chen, J.-F.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-05-01
- Volume
- 14
- Issue
- 15
- Pages
- 1512-1524
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2094888594
- Cited by
- 186
- References
- 39
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.